Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclo-Z is an investigational combination therapy developed by the VA Office of Research and Development for the treatment of type 2 diabetes mellitus. It consists of zinc and the cyclic dipeptide cyclo(histidyl-proline) (CHP), a naturally occurring metabolite of thyrotropin-releasing hormone. CHP acts as a zinc-binding ligand that facilitates the intestinal absorption and cellular uptake of zinc. Zinc is a critical cofactor for numerous enzymes involved in glucose metabolism and is essential for the proper synthesis, storage, and secretion of insulin. Furthermore, zinc has been shown to exert insulin-mimetic effects by activating the insulin receptor and downstream signaling pathways. By optimizing zinc homeostasis, Cyclo-Z aims to improve glycemic control and insulin sensitivity in patients with type 2 diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclo-Z.